Home » Stocks » VINC

Vincerx Pharma, Inc. (VINC)

Stock Price: $16.86 USD 0.52 (3.18%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 295.14M
Revenue (ttm) n/a
Net Income (ttm) -10.72M
Shares Out 17.51M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $16.86
Previous Close $16.34
Change ($) 0.52
Change (%) 3.18%
Day's Open 16.13
Day's Range 16.13 - 17.07
Day's Volume 34,785
52-Week Range 9.35 - 26.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021

3 weeks ago - GlobeNewsWire

VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models

1 month ago - GlobeNewsWire

PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...

1 month ago - GlobeNewsWire

PALO ALTO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced that it will redeem all of its outstanding public warrants (the “Public Warrant...

1 month ago - GlobeNewsWire

PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...

1 month ago - GlobeNewsWire

License agreement with Bayer AG secures oncology portfolio including clinical-stage PTEFb/CDK9 inhibitor with encouraging Phase 1 activity

1 month ago - GlobeNewsWire

PALO ALTO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...

2 months ago - GlobeNewsWire

PALO ALTO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...

4 months ago - GlobeNewsWire

Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020

4 months ago - GlobeNewsWire

About VINC

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincerx Pharma, Inc. is based in Palo Alto, California.

Industry
Biotechnology
Founded
2019
Stock Exchange
NASDAQ
Ticker Symbol
VINC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Vincerx Pharma stock is "Strong Buy" and the 12-month stock price forecast is 33.00.

Price Target
$33.00
Analyst Consensus: Strong Buy